HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Karim Fizazi Selected Research

Estramustine

12/2020Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial.
1/2016Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.
7/2015Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
1/2012A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
12/2011The use of estramustine phosphate in the modern management of advanced prostate cancer.
5/2009Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
11/2007Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
9/2004High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Karim Fizazi Research Topics

Disease

221Prostatic Neoplasms (Prostate Cancer)
10/2022 - 03/2002
74Neoplasms (Cancer)
07/2022 - 02/2002
59Neoplasm Metastasis (Metastasis)
02/2022 - 03/2002
37Pain (Aches)
07/2022 - 03/2003
25Disease Progression
01/2022 - 06/2014
16Fatigue
03/2022 - 01/2012
13Seminoma
01/2022 - 08/2003
13Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
10/2021 - 10/2004
12Renal Cell Carcinoma (Grawitz Tumor)
01/2020 - 07/2003
9Hypertension (High Blood Pressure)
01/2022 - 05/2011
7Circulating Neoplastic Cells
01/2020 - 01/2016
6Febrile Neutropenia
01/2022 - 02/2013
6Asthenia
01/2022 - 04/2015
6Neutropenia
01/2022 - 02/2013
6Bone Resorption
01/2013 - 07/2003
6Carcinoma (Carcinomatosis)
07/2009 - 10/2002
5Breast Neoplasms (Breast Cancer)
06/2022 - 04/2009
5Edema (Dropsy)
03/2022 - 11/2012
5Nausea
01/2022 - 05/2013
4Pneumonia (Pneumonitis)
01/2022 - 04/2015
4Diarrhea
10/2021 - 09/2012
4Testicular Neoplasms (Testicular Cancer)
01/2021 - 08/2011
4Kidney Neoplasms (Kidney Cancer)
01/2020 - 04/2014
3Cancer Pain
01/2022 - 01/2013
3Adenocarcinoma
01/2021 - 12/2007
3Hypocalcemia
02/2019 - 02/2014
3Osteonecrosis (Kienbock's Disease)
02/2019 - 01/2012
3Seizures (Absence Seizure)
01/2019 - 09/2012
3Hypokalemia
01/2018 - 05/2011
3Urinary Bladder Neoplasms (Bladder Cancer)
10/2016 - 07/2006

Drug/Important Bio-Agent (IBA)

61Docetaxel (Taxotere)FDA Link
03/2022 - 09/2004
56AndrogensIBA
02/2022 - 03/2002
38Prostate-Specific Antigen (Semenogelase)IBA
01/2022 - 07/2003
36enzalutamideIBA
03/2022 - 09/2012
36Prednisone (Sone)FDA LinkGeneric
02/2022 - 05/2011
34Abiraterone AcetateIBA
02/2022 - 05/2011
28abirateroneIBA
01/2022 - 05/2011
27Hormones (Hormone)IBA
10/2022 - 10/2008
24Androgen Receptors (Androgen Receptor)IBA
02/2022 - 03/2002
17Cisplatin (Platino)FDA LinkGeneric
01/2022 - 02/2002
16cabazitaxelFDA Link
03/2022 - 06/2014
16DenosumabFDA Link
02/2019 - 04/2009
14darolutamideIBA
07/2022 - 08/2014
13Biomarkers (Surrogate Marker)IBA
01/2022 - 03/2010
11Pharmaceutical PreparationsIBA
01/2022 - 07/2003
10taxaneIBA
06/2022 - 01/2010
10Poly(ADP-ribose) Polymerase InhibitorsIBA
05/2022 - 01/2020
10Diphosphonates (Bisphosphonates)IBA
02/2016 - 04/2009
8EstramustineFDA Link
12/2020 - 09/2004
8Zoledronic Acid (Zometa)FDA Link
02/2019 - 03/2011
7AntigensIBA
10/2022 - 05/2015
7Proteins (Proteins, Gene)FDA Link
01/2022 - 03/2002
7IpilimumabIBA
01/2021 - 06/2014
7collagen type I trimeric cross-linked peptideIBA
09/2015 - 04/2009
7Monoclonal AntibodiesIBA
07/2015 - 04/2009
6Etoposide (VP 16)FDA LinkGeneric
01/2022 - 10/2002
6Carboplatin (JM8)FDA LinkGeneric
01/2022 - 12/2006
6Immune Checkpoint InhibitorsIBA
01/2022 - 10/2017
6Alkaline PhosphataseIBA
01/2020 - 01/2013
5Taxoids (Taxanes)IBA
03/2022 - 06/2013
5olaparibIBA
01/2022 - 01/2020
5TabletsIBA
01/2022 - 01/2016
5L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
10/2021 - 12/2002
5Biological ProductsIBA
06/2021 - 12/2002
5Testosterone (Sustanon)FDA Link
12/2020 - 08/2014
5RadiopharmaceuticalsIBA
01/2020 - 05/2009
5Androgen Receptor AntagonistsIBA
10/2019 - 12/2017
4PlacebosIBA
02/2022 - 01/2018
4Mitoxantrone (Novantrone)FDA LinkGeneric
01/2020 - 01/2013
4Hemoglobins (Hemoglobin)IBA
01/2020 - 07/2015
4Radium-223IBA
01/2019 - 11/2015
4GemcitabineFDA Link
01/2019 - 09/2003
4CreatinineIBA
09/2015 - 04/2009
4Endothelins (Endothelin)IBA
05/2013 - 07/2003
3talazoparibIBA
06/2022 - 01/2021
3Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
05/2022 - 01/2020
3Adrenal Cortex Hormones (Corticosteroids)IBA
03/2022 - 01/2016
3antiarrhythmic peptide (AAP)IBA
02/2022 - 11/2018
3NivolumabIBA
01/2022 - 10/2016
3DNA (Deoxyribonucleic Acid)IBA
01/2022 - 01/2018
3Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2022 - 10/2019
3Opiate AlkaloidsIBA
01/2022 - 01/2013
3rucaparibIBA
12/2021 - 01/2020
3Granulocyte Colony-Stimulating Factor (G-CSF)IBA
11/2020 - 02/2013
3cabozantinibIBA
01/2020 - 01/2016
3EverolimusFDA Link
12/2017 - 12/2010
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2017 - 01/2013
3alpha-Fetoproteins (alpha-Fetoprotein)IBA
02/2016 - 10/2004
3sipuleucel-T (APC8015)FDA Link
11/2015 - 05/2015
3Chorionic Gonadotropin (Human Chorionic Gonadotropin)FDA LinkGeneric
12/2014 - 08/2003
3RANK LigandIBA
10/2013 - 07/2003
3ZD4054IBA
05/2013 - 07/2012

Therapy/Procedure

171Castration
07/2022 - 03/2002
113Therapeutics
10/2022 - 03/2003
88Drug Therapy (Chemotherapy)
06/2022 - 02/2002
21Radiotherapy
01/2022 - 08/2003
7Aftercare (After-Treatment)
01/2022 - 05/2009
6Immunotherapy
01/2020 - 12/2006
4Precision Medicine
06/2021 - 01/2014
4Duration of Therapy
11/2020 - 10/2011